MarketPeel
Insider Trading Intelligence
IG

II Robert C. Goeltz

RCUS
CHIEF FINANCIAL OFFICER · ARCUS BIOSCIENCES, INC. · CIK 0001653881
FILING MIX · LIFETIME43%/57%
BUYS
15
SELLS
20
TOTAL VALUE
$1.52M
COMPANIES
1
ACTIVE SINCE
Aug 2020
HOLDINGS NOW
84,161
AVG SELL PX
$21.46
TRADE KIND
SHOWING 35 / 35
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
18 backtested trades · 8 horizons · 16 pending
Forward-return performance of every backtestable P/S trade by II Robert C. Goeltz, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d18+33.33%-0.95%+1.06%-2.02%+0.95%
14d18+61.11%-5.65%+1.16%-6.80%-6.00%
30d18+88.89%-10.22%+1.73%-11.95%-12.73%
60d18(1 pending)+82.35%-18.08%+1.06%-19.14%-20.98%
90d18(1 pending)+76.47%-12.51%-0.28%-12.23%-12.98%
180d18(1 pending)+76.47%-20.40%-0.32%-20.83%-30.13%
1y18(6 pending)+91.67%-13.13%+4.88%-18.01%-10.44%
2y18(7 pending)+90.91%-40.37%+24.58%-64.96%-63.29%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
RCUS · 84,161 shares · as of May 11, 2026
062,500125,000187,500250,000202120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 15 buys / 20 sellsCOVERAGE · 24 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
RCUS
ARCUS BIOSCIENCES, INC.
SALE10b5-1
10b5-1 plan
7,763$25.63$199.0K84,161May 11, 2026May 12, 2026View →
RCUS
ARCUS BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
24,00091,924Jan 23, 2026Jan 26, 2026View →
RCUS
ARCUS BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
96,00096,000Jan 23, 2026Jan 26, 2026View →
RCUS
ARCUS BIOSCIENCES, INC.
SALE10b5-1
10b5-1 plan
6,552$23.38$153.2K67,924Dec 31, 2025Jan 2, 2026View →
RCUS
ARCUS BIOSCIENCES, INC.
SALE10b5-1
10b5-1 plan
5,960$22.16$132.1K74,476Dec 17, 2025Dec 18, 2025View →
RCUS
ARCUS BIOSCIENCES, INC.
SALE10b5-1
10b5-1 plan
6,702$21.88$146.7K80,436Dec 16, 2025Dec 18, 2025View →
RCUS
ARCUS BIOSCIENCES, INC.
SALE10b5-1
10b5-1 plan
5,000$25.00$125.0K87,138Nov 26, 2025Nov 26, 2025View →
RCUS
ARCUS BIOSCIENCES, INC.
SALE10b5-1
10b5-1 plan
5,000$20.00$100.0K92,138Oct 28, 2025Oct 29, 2025View →
RCUS
ARCUS BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
150,000150,000Jan 23, 2025Jan 27, 2025View →
RCUS
ARCUS BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
37,00097,138Jan 23, 2025Jan 27, 2025View →
RCUS
ARCUS BIOSCIENCES, INC.
SALE10b5-1
10b5-1 plan
3,594$15.00$53.9K60,138Dec 31, 2024Jan 3, 2025View →
RCUS
ARCUS BIOSCIENCES, INC.
SALE
Chief Financial Officer
10,099$16.08$162.4K63,732Dec 15, 2024Dec 17, 2024View →
RCUS
ARCUS BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
21,30073,131Jan 23, 2024Jan 25, 2024View →
RCUS
ARCUS BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
86,60086,600Jan 23, 2024Jan 25, 2024View →
RCUS
ARCUS BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
22,00073,831Jan 23, 2024Feb 23, 2024View →
RCUS
ARCUS BIOSCIENCES, INC.
SALE10b5-1
10b5-1 plan
2,004$20.00$40.1K51,831Jan 2, 2024Jan 4, 2024View →
RCUS
ARCUS BIOSCIENCES, INC.
SALE
Chief Financial Officer
2,808$18.09$50.8K53,835Dec 19, 2023Dec 20, 2023View →
RCUS
ARCUS BIOSCIENCES, INC.
SALE
Chief Financial Officer
2,749$17.74$48.8K56,643Dec 18, 2023Dec 20, 2023View →
RCUS
ARCUS BIOSCIENCES, INC.
SALE10b5-1
10b5-1 plan
4,049$20.04$81.1K59,392Jun 7, 2023Jun 9, 2023View →
RCUS
ARCUS BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
138,200138,200Jan 23, 2023Jan 25, 2023View →
RCUS
ARCUS BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
34,00063,441Jan 23, 2023Jan 25, 2023View →
RCUS
ARCUS BIOSCIENCES, INC.
SALE
Chief Financial Officer
2,066$30.66$63.3K11,953Dec 16, 2022Dec 16, 2022View →
RCUS
ARCUS BIOSCIENCES, INC.
SALE
Chief Financial Officer
387$31.23$12.1K11,566Dec 16, 2022Dec 16, 2022View →
RCUS
ARCUS BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
62,50062,500Mar 8, 2022Mar 10, 2022View →
RCUS
ARCUS BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
15,50022,519Mar 8, 2022Mar 10, 2022View →
RCUS
ARCUS BIOSCIENCES, INC.
SALE
Chief Financial Officer
88$39.67$3.5K7,414Dec 17, 2021Dec 20, 2021View →
RCUS
ARCUS BIOSCIENCES, INC.
SALE
Chief Financial Officer
171$40.57$6.9K7,243Dec 17, 2021Dec 20, 2021View →
RCUS
ARCUS BIOSCIENCES, INC.
SALE
Chief Financial Officer
224$41.42$9.3K7,019Dec 17, 2021Dec 20, 2021View →
RCUS
ARCUS BIOSCIENCES, INC.
SALE
Chief Financial Officer
138$38.79$5.4K7,502Dec 17, 2021Dec 20, 2021View →
RCUS
ARCUS BIOSCIENCES, INC.
SALE
Chief Financial Officer
354$39.59$14.0K7,771Dec 16, 2021Dec 20, 2021View →
RCUS
ARCUS BIOSCIENCES, INC.
SALE
Chief Financial Officer
131$40.46$5.3K7,640Dec 16, 2021Dec 20, 2021View →
RCUS
ARCUS BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
75,00075,000Jan 19, 2021Jan 20, 2021View →
RCUS
ARCUS BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
12,50017,500Jan 19, 2021Jan 20, 2021View →
RCUS
ARCUS BIOSCIENCES, INC.
PURCHASE
Chief Financial Officer
5,000$21.57$107.8K5,000Sep 9, 2020Sep 9, 2020View →
RCUS
ARCUS BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
250,000250,000Aug 3, 2020Aug 4, 2020View →
Other insiders · RCUS
Loading peer insiders…
About this filer
CIK 0001653881
ROLE
Chief Financial Officer
PRIMARY
RCUS
COMPANIES
1
ACTIVE SINCE
Aug 2020
MARKETPEEL · /INSIDER/0001653881DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback